Skip to main content

Antithrombotic- and Thrombolytic-Related Intracerebral Hemorrhage

  • Chapter
  • First Online:
Intracerebral Hemorrhage Therapeutics

Abstract

Intracerebral hemorrhage related to anticoagulant therapy represents a neurologic emergency. This chapter reviews the evidence of anticoagulation reversal treatment and further elucidates management of intracerebral hemorrhage occurring in relation to antithrombotic treatment and thrombolysis, as well as heparin. Prothrombin concentrate can effectively reverse vitamin K antagonist therapy and should be immediately administered in acute intracerebral hemorrhage associated with vitamin K antagonist therapy. For non-vitamin K antagonist-associated intracerebral hemorrhage, recent observational data show a similar rate of hematoma expansion than with vitamin K antagonists. Specific antidotes for non-vitamin K antagonist reversal are either available (idarucizumab for reversal of dabigatran) or in development (for factor Xa inhibitors). Importantly, in case of intracerebral hemorrhage associated with antiplatelet therapy, cessation of antiplatelet therapy seems sufficient in most cases, and platelet infusions should not be given. Despite all recent advances, anticoagulation-related intracerebral hemorrhage still is associated with unfavorable clinical outcome and further efforts need to be taken to define the optimal medical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literature

  1. Fisher CM. Hypertensive cerebral hemorrhage. Demonstration of the source of bleeding. J Neuropathol Exp Neurol. 2003;62(1):104–7.

    Article  PubMed  Google Scholar 

  2. Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7(1):1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83(2):124–37.

    Article  PubMed  Google Scholar 

  4. Greenberg SM, Nandigam RN, Delgado P, Betensky RA, Rosand J, Viswanathan A, et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke. 2009;40(7):2382–6.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kovari E, Charidimou A, Herrmann FR, Giannakopoulos P, Bouras C, Gold G. No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy. Acta Neuropathol Commun. 2015;3:49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64.

    Article  CAS  PubMed  Google Scholar 

  7. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824–36.

    Article  CAS  PubMed  Google Scholar 

  8. Schlunk F, Greenberg SM. The pathophysiology of intracerebral hemorrhage formation and expansion. Transl Stroke Res. 2015;6(4):257–63.

    Article  CAS  PubMed  Google Scholar 

  9. Greenberg CH, Frosch MP, Goldstein JN, Rosand J, Greenberg SM. Modeling intracerebral hemorrhage growth and response to anticoagulation. PLoS One. 2012;7(10):e48458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Horstmann S, Rizos T, Lauseker M, Mohlenbruch M, Jenetzky E, Hacke W, et al. Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. J Neurol. 2013;260(8):2046–51.

    Article  CAS  PubMed  Google Scholar 

  11. Bejot Y, Cordonnier C, Durier J, Aboa-Eboule C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013;136(Pt 2):658–64.

    Article  PubMed  Google Scholar 

  12. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68(2):116–21.

    Article  CAS  PubMed  Google Scholar 

  13. Steiner T, Poli S, Griebe M, Husing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566–73.

    Article  CAS  PubMed  Google Scholar 

  14. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71(14):1084–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76(14):1238–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Biffi A, Battey TW, Ayres AM, Cortellini L, Schwab K, Gilson AJ, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology. 2011;77(20):1840–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Pezzini A, Grassi M, Paciaroni M, Zini A, Silvestrelli G, Del Zotto E, et al. Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. Neurology. 2014;82(6):529–35.

    Article  CAS  PubMed  Google Scholar 

  18. Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5(3):197–201.

    Article  PubMed  Google Scholar 

  19. Hanger HC, Fletcher VJ, Wilkinson TJ, Brown AJ, Frampton CM, Sainsbury R. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol. 2008;255(3):347–52.

    Article  CAS  PubMed  Google Scholar 

  20. Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used? Int J Stroke. 2016;11(7):748–58.

    Article  PubMed  Google Scholar 

  21. Rizos T, Jenetzky E, Herweh C, Hug A, Hacke W, Steiner T, et al. Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol [Clinical Trial]. 2010;67(6):788–93.

    Google Scholar 

  22. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):204S–33S.

    Article  CAS  PubMed  Google Scholar 

  23. Neal M, Crowther M, Douketis J, Verhovsek M, Stidley C, Garcia D. Reversal of vitamin K antagonist-associated coagulopathy: a survey of current practice. Thromb Res. 2008;122(6):864–6.

    Article  CAS  PubMed  Google Scholar 

  24. Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res. 2012;130(6):833–40.

    Article  CAS  PubMed  Google Scholar 

  25. Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of Antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical care society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6–46.

    Article  CAS  PubMed  Google Scholar 

  26. Laible M, Jenetzky E, Beynon C, Muller OJ, Sander P, Schuler S, et al. Adverse events following international normalized ratio reversal in intracerebral hemorrhage. Cerebrovasc Dis. 2016;42(5–6):446–54.

    Article  CAS  PubMed  Google Scholar 

  27. Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87.

    Article  CAS  Google Scholar 

  28. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–43.

    PubMed  CAS  Google Scholar 

  29. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

    Article  CAS  PubMed  Google Scholar 

  30. Pfeilschifter W, Farahmand D, Niemann D, Ikenberg B, Hohmann C, Abruscato M, et al. Estimating the quantitative demand of NOAC antidote doses on stroke units. Cerebrovasc Dis. 2016;42(5–6):415–20.

    Article  CAS  PubMed  Google Scholar 

  31. Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73(2):169–77.

    Article  PubMed  Google Scholar 

  32. Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology. 2017;88(18):1693–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Purrucker JC, Rizos T, Haas K, Wolf M, Khan S, Heuschmann PU, et al. Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants. Neurocrit Care. 2017;27:208.

    Article  CAS  PubMed  Google Scholar 

  34. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42(12):3594–9.

    Article  PubMed  Google Scholar 

  35. Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44(3):771–8.

    Article  CAS  PubMed  Google Scholar 

  36. Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care. 2016;20(1):115.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation [Comparative Study]. 2011;124(14):1573–9.

    Article  CAS  Google Scholar 

  38. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.

    Article  CAS  PubMed  Google Scholar 

  39. Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med. 2016;129(11S):S64–72.

    Article  CAS  PubMed  Google Scholar 

  40. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511–20.

    Article  CAS  PubMed  Google Scholar 

  41. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–41.

    Article  CAS  PubMed  Google Scholar 

  42. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2–10.

    Article  CAS  PubMed  Google Scholar 

  44. Gumbinger C, Gruschka P, Bottinger M, Heerlein K, Barrows R, Hacke W, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke. 2012;43(1):240–2.

    Article  PubMed  Google Scholar 

  45. von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, et al. The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46(10):2981–6.

    Article  Google Scholar 

  46. Whiteley WN, Emberson J, Lees KR, Blackwell L, Albers G, Bluhmki E, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925–33.

    Article  PubMed  Google Scholar 

  47. Yaghi S, Boehme AK, Dibu J, Leon Guerrero CR, Ali S, Martin-Schild S, et al. Treatment and outcome of thrombolysis-related hemorrhage: a multicenter retrospective study. JAMA Neurol. 2015;72(12):1451–7.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–13.

    Article  PubMed  Google Scholar 

  49. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27(10):1783–7.

    Article  CAS  PubMed  Google Scholar 

  50. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  51. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175–81.

    Article  CAS  PubMed  Google Scholar 

  52. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127–37.

    Article  CAS  PubMed  Google Scholar 

  53. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P, Investigators C. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39(11):2993–6.

    Article  CAS  PubMed  Google Scholar 

  54. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011;42(9):2431–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thorsten Steiner .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Purrucker, J.C., Flaherty, M.L., Rodriguez, G., Chaudhry, S., Siddiqui, F., Steiner, T. (2018). Antithrombotic- and Thrombolytic-Related Intracerebral Hemorrhage. In: Ovbiagele, B., Qureshi, A. (eds) Intracerebral Hemorrhage Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-77063-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-77063-5_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-77062-8

  • Online ISBN: 978-3-319-77063-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics